The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1803 participants.

Also called NCT04437654

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,803 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04437654
Other papers using this trial's data
  • Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk The New England journal of medicine, 2026-09-24 DOI, PubMed 42663303

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04437654. Randomized; no masking; primary purpose treatment. Start 2020-07-28 (actual); primary completion 2025-08-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Condition
Atrial Fibrillation Patients With Intermediate Stroke Risk
Intervention (Drug)
Anticoagulation group(DOAC group)
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct04437654
Content hash
8d7ca11bc6fb1a3abf39361317d6a08abe77171ba4e2594b58c1b22c3ca64557